- recruitingPhase I and Phase II (Integrated)- First administration to humans
Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want to evaluate the safety and the immunogenicity of a vaccine that includes a first administration of the ChAdOx1.tHIVconsvX product and a second one with MVA.tHIVconsvX in HIV-1 positive adults treated early and able to control the infection for a long time.
This early-stage clinical trial tests a new two-step vaccine for adults living with HIV. Researchers want to see if the vaccine is safe and if it helps the immune system recognise the virus. It is for people who started treatment early and have kept their HIV well controlled.
Italy - recruitingHuman Pharmacology (Phase I)- Other
A clinical study of MK-4646 in people with HIV (MK-4646-003)
This early-stage clinical study looks at an experimental medicine called MK-4646 in adults living with HIV. Researchers want to find out how safe the medicine is, how the body handles it, and what side effects it might cause. It is open to adults aged 18 and older.
Romania - recruitingHuman Pharmacology (Phase I)- First administration to humans
MK-4646 Single Ascending Dose Study and DDI in Healthy Participants
This study is looking at a new medicine called MK-4646. It's for people living with HIV. Researchers want to see if it's safe, how much is needed, and how it works with other medicines. Only healthy adult men can join this first study.
Belgium - recruitingTherapeutic confirmatory (Phase III)
(CAbotégravir LENacapavir DUal Long Acting). Phase II, Pilot study, open label, multicenter, evaluating dual antiretroviral therapy with long-acting cabotegravir/lenacapavir IMEA 069 - CALENDULA
This study is looking at two long-acting HIV medicines given together to see how well they control the virus. It's for adults living with HIV and aims to find out if this combination is effective and safe over 48 weeks.
France - recruitingHuman Pharmacology (Phase I)- Other
A clinical study of MK-4646 in healthy people (MK-4646-002)
This study is looking at a new medicine called MK-4646 in healthy people to prepare for future trials in those with HIV. It's a very early stage study, focused on understanding how the drug works and any initial side effects.
Belgium - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption.
This study looks at new medicines (Budigalimab and ABBV-382) for people with HIV. It tests if these medicines can help control HIV without daily treatment, by carefully pausing regular medication. The goal is to see if HIV stays low after stopping usual drugs.
Germany · Denmark · Italy - recruitingPhase IV
A study looking at using two drugs as dual anti-HIV therapy in people who have previously had brain injury caused by HIV
This study looks at a two-drug treatment (Dovato) for HIV in people who've had past HIV-related brain issues. It aims to see if this simpler treatment is safe and works well even after previous brain involvement.
United Kingdom · England - active not recruitingPHASE3
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
This study looks at the safety of a two-in-one medicine called DOR/ISL for adults with HIV-1. It's for people who have already taken this medicine in other research studies. The main goal is to see how well people tolerate it over time.
United States · Argentina · Australia - recruitingNA
#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
This study looks at whether dedicated HIV teams in hospitals can increase HIV testing for specific health problems linked to HIV, aiming for earlier diagnosis and better health. It involves hospitals across Europe.
Belgium · France · Germany